NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bile Ducts, Intrahepatic
/ drug effects
Biliary Tract Neoplasms
/ drug therapy
Cholangiocarcinoma
/ drug therapy
Cisplatin
/ administration & dosage
Cytidine Monophosphate
/ administration & dosage
Deoxycytidine
/ administration & dosage
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Survival Rate
Treatment Outcome
Young Adult
Gemcitabine
NUC-1031
advanced biliary tract cancer
cisplatin
first-line treatment
gemcitabine
objective response rate
overall survival
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
7
5
2020
medline:
18
3
2021
entrez:
7
5
2020
Statut:
ppublish
Résumé
Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal of NUC-1031/cisplatin in the Phase Ib ABC-08 study suggested that this combination may represent a more efficacious therapy than gemcitabine/cisplatin for patients with aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients ≥18 years with untreated histologically/cytologically-confirmed aBTC (including cholangiocarcinoma, gallbladder or ampullary cancer); randomized (1:1) to NUC-1031 (725 mg/m
Identifiants
pubmed: 32374623
doi: 10.2217/fon-2020-0247
doi:
Substances chimiques
NUC-1031
0
Deoxycytidine
0W860991D6
Cytidine Monophosphate
F469818O25
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Banques de données
ClinicalTrials.gov
['NCT04163900']
Types de publication
Clinical Trial Protocol
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM